RxDoctor Payments Data

Richard Strecker, MD

Ophthalmology · Hingham, MANPI 1063419950

Payments from drug & device makers

$1,934in general payments, 2019–2025

Across 73 payments — averaging $26.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Tarsus Pharmaceuticals, Inc.$609
  • Sun Pharmaceutical Industries Inc.$424
  • Alcon$298
  • AbbVie$185
  • Bausch & Lomb Americas Inc.$138
  • Aerie Pharmaceuticals, Inc.$72
  • plus $208 from 6 others

What the payments were for

  • Food & beverage$1,91899%
  • Education$151%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,934 in reported general payments places this provider in the 60th percentile of 653 ophthalmology providers in Massachusetts.

See all ophthalmology providers in Massachusetts

Medicare billing

Part B allowed, 2024
$371,380
Medicare patients
1,157
Services billed
2,808

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine14$25,738
RhopressaNetarsudil Mesylate39$15,295
ProlensaBromfenac Sodium34$13,936
XiidraLifitegrast13$12,014
CequaCyclosporine16$11,148
LumiganBimatoprost18$8,912
Latanoprost603$7,829
TafluprostTafluprost/Pf31$5,301
VyzultaLatanoprostene Bunod11$5,244
Brimonidine Tartrate80$3,337
Travoprost25$3,198
Bromfenac Sodium21$3,053
Acetazolamide45$2,924
Timolol Maleate131$2,305
Atropine Sulfate39$1,273

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$185$34,65032 claims
Bausch & Lomb Americas Inc.Xiidra, Vyzulta$138$17,25824 claims
Aerie Pharmaceuticals, Inc.Rhopressa$72$15,29539 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa$61$13,93634 claims
Sun Pharmaceutical Industries Inc.Cequa$424$11,14816 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 653 ophthalmology providers in Massachusetts.

Other ophthalmology in Hingham

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →